Abstract:5538 Background: Cadonilimab, an anti-PD-1/CTLA4 bi-specific antibody, and Nimotuzumab, an anti-EGFR monoclonal antibody, have demonstrated effectiveness in treating persistent, recurrent, or metastatic (P/R/M) cervical cancer individually. However, the exploration of combined bi-specific immunotherapy and anti-EGFR target therapy remains unexplored in P/R/M gynecological cancer. Methods: This open-label, prospective single-arm phase II study (NCT05606263). Eligible participants were P/R/M gynecological cancer patients who declined or couldn’t tolerate chemotherapy, or had failed first-line or subsequent treatments, irrespective of PD-L1 status. Patients received Cadonilimab at 6 mg/kg plus Nimotuzumab at a dose of 400 mg every two weeks. The primary endpoint included safety and objective response rate (ORR), with secondary endpoints comprising progression-free survival (PFS) and overall survival (OS). Results: From July 2022 to February 2024, twenty-nine P/R/M gynecological cancer patients received at least one dose of cadonilimab plus Nimotuzumab, including 22 (75.9%) with cervical cancer, 4 (13.8%) with endometrial carcinoma, and 3 (10.3%) with vulva cancer. The median age was 60 years (range: 39–80 years). Reasons for participating in this clinical trial included refusal of chemotherapy (7/29), inability to tolerate chemotherapy (7/29), and failure of first-line or subsequent lines of systemic therapy (15/29). Among them, 5 patients progressed after PD-1/PD-L1 treatment. After a median follow-up of 6 months (range: 1–18), the best response was observed in 17 patients, with 3 achieving complete response (CR) and 14 partial response (PR). Notably 2 patients relapsed after PD-1 treatment. The ORR was 58.6% (95% CI, 39.7–77.7). Additionally 6 patients achieved stable disease (SD), while 6 patients experienced disease progression. The median PFS and OS were not reached, but the 6-month PFS rate was 58.1% (95% CI, 35.5–75.2), and the 6-month OS rate was 76.5% (95% CI, 54.6–88.8). Adverse events (AEs) were generally manageable and tolerable (Grade 1-2), including hypothyroidism (13.8%), immune-mediated hepatitis (13.8%), rash maculo-papular (6.9%), thrombocytopenia (6.9%) and nephritis (3.4%). Conclusions: To the best of our knowledge, this represents the inaugural clinical report on the de-chemotherapy regimen of Cadonilimab plus Nimotuzumab for P/R/M gynecological cancer. The combination exhibited a promising tumor response rate (58.6%), surpassing the 32.3% observed with Cadonilimab alone, and demonstrated a manageable safety profile. These findings suggest the potential of bi-specific immunotherapy coupled with anti-EGFR target therapy especially in patients who are resistant to chemotherapy or intolerant to it, even in cases where single- specific immunotherapy has previously failed. Clinical trial information: NCT05606263 .

Advanced cervix cancer patient with chemotherapy-induced grade IV myelosuppression achieved complete remission with cadonilimab: A case report

A Multicenter, Open-Label Phase Ib/II Study of Cadonilimab (anti PD-1 and CTLA-4 Bispecific Antibody) Monotherapy in Previously Treated Advanced Non-Small-cell Lung Cancer (AK104-202 Study).

The safety and efficacy of cadonilimab in the treatment of advanced and metastatic cervical cancer: A retrospective, real-world study.

Safety and clinical activity of cadonilimab, an anti PD-1/CTLA-4 bispecific antibody, for patients with persistent, recurrent, or metastatic cervical cancer (R/M CC): A retrospective, real-world study.

Cadonilimab is effective and safe in recurrent cervical cancer

Cadonilimab combined with chemotherapy with or without bevacizumab as first-line treatment in recurrent or metastatic cervical cancer (COMPASSION-13): a phase 2 study

Efficacy and safety of cadonilimab, an anti-PD-1/CTLA4 bi-specific antibody, in previously treated recurrent or metastatic (R/M) cervical cancer: a multicenter, open-label, single-arm, phase II trial (075)

Second-line monotherapy with a PD-1/CTLA-4 inhibitor effectively treated multiple brain and lung metastases of cervical cancer: a case report

Programmed Cell Death-1 Inhibitor Combination Treatment for Recurrent Proficient Mismatch Repair/ Miscrosatellite-Stable Type Endometrial Cancer: A Case Report.

947P the Efficacy and Safety of Cadonilimab Combined with Lenvatinib for First-Line Treatment of Advanced Hepatocellular Carcinoma: A Phase Ib/II Clinical Trial

Cadonilimab plus platinum-based chemotherapy with or without bevacizumab as first-line treatment for persistent, recurrent, or metastatic cervical cancer (COMPASSION-16): a randomised, double-blind, placebo-controlled phase 3 trial in China

The efficacy and safety of a novel PD‐1/CTLA‐4 bispecific antibody cadonilimab (AK104) in advanced non‐small cell lung cancer: A multicenter retrospective observational study

Efficacy and safety of cadonilimab plus anti-EGFR monoclonal antibody as de-chemotherapy regimen in persistent, recurrent, or metastatic gynecologic cancer.

Efficacy, Safety and DNA Methylation Analysis of Cadonilimab Combined with Taxane and Cisplatin As the First-Line Treatment in Patients with Advanced Esophageal Squamous Cell Carcinoma (ESCC): an Open-Label, Multicenter Phase II Trial– Updated Results from AK104-IIT-014.

Good response to cadonilimab as first-line treatment in superaged patient with advanced gastric cancer: a case report

Cadonilimab Plus Lenvatinib in Patients with Advanced Endometrial Cancer: A Multicenter, Single-Arm, Phase II Trial.

Long Survival after Immunotherapy Plus Paclitaxel in Advanced Intrahepatic Cholangiocarcinoma: A Case Report and Review of Literature

The Combined Use of Chemotherapy and Radiotherapy with PD-1 Inhibitor, Pembrolizumab, in Advanced Cervical Cancer: A Case Report

Efficacy of cadonilimab and anlotinib combination in treating multiple drug‐resistant pulmonary large cell neuroendocrine carcinoma: A case report and literature review

Case report: Remarkable response to sintilimab, lenvatinib, and nab-paclitaxel in postoperative metastatic chemotherapy-resistant combined hepatocellular-cholangiocarcinoma

Case Report: Significant Response to Immune Checkpoint Inhibitor Camrelizumab in a Heavily Pretreated Advanced ER+/HER2− Breast Cancer Patient With High Tumor Mutational Burden